SweetValueLab
Write for us

Waters Corporation — Intrinsic Value & Fair Price

WAT
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0001000697waters.comAbout WAT
Last close · Oct 16, 2026436.95−7.20 (−1.62%)
Market cap$42.9B
Model value · DCF · Perpetuity growth · 5y
253.30
Waters closed at $436.95 — overvalued by 73% vs model.
170.91the model's range495.85

DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
114.34 – 680.27
Wall St. target
477.50 8% below
Above model, 1y
17 of 20 days

Price and model value

Embed this card

WAT's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Research on WAT

No posts on WAT yet.
Studied WAT from its filings? Guest posts are reviewed before they go live.Write about WAT →

How it is valued

Valued asProfitable Growth
Low/slowing growth (~3% recent)High profitability (20% net margin)Highly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2025
P/E
40.6×
EV / EBITDA
42.8×
FCF yield
2.1%
Dividend yield, TTM
0.00%
Beta
1.15
Cost of capital (WACC)
9.57%
Full financials

Analyst actions

third-party, quoted
10-07Barclays · target500.00
10-01Guggenheim · target490.00
09-21Goldman Sachs · target515.00
09-09UBS · “Buy” from “Neutral”upgrade
Ratings, targets and estimates

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just WAT. No account.

About Waters

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

CEO
Udit Batra
Headquarters
Milford, MA
Employees
7,900
IPO
1995-11-17
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.